[關(guān)鍵詞]
[摘要]
目的 探討解郁安神顆粒聯(lián)合氟伏沙明治療抑郁癥的臨床療效。方法 選取2023年1月—2024年4月開(kāi)灤精神衛(wèi)生中心收治的102例抑郁癥患者,按隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組,每組各51例。對(duì)照組睡前口服馬來(lái)酸氟伏沙明片,100 mg/次,1次/d。治療組在對(duì)照組治療基礎(chǔ)上開(kāi)水沖服解郁安神顆粒,5 g/次,2次/d。兩組療程均為6周。觀察兩組的臨床療效,比較兩組治療前和治療2、4、6周17項(xiàng)漢密爾頓抑郁量表(HAMD-17)積分及治療前后漢密爾頓焦慮量表(HAMA)、癥狀自評(píng)量表(SCL-90)、睡眠狀況自評(píng)量表(SRSS)、日常生活能力評(píng)定量表(ADL)評(píng)分和事件相關(guān)電位P300參數(shù)變化情況。結(jié)果 治療后,治療組總有效率是94.12%,顯著高于對(duì)照組的80.39%(P<0.05)。治療后,兩組治療2、4、6周HAMD-17積分均低于同組治療前(P<0.05);治療2、4、6周治療組HAMD-17積分均低于同期對(duì)照組(P<0.05)。治療后,兩組HAMA、SCL-90、SRSS評(píng)分均低于同組治療前,ADL評(píng)分均顯著增高(P<0.05);治療后,治療組HAMA、SCL-90、SRSS評(píng)分均低于對(duì)照組,ADL評(píng)分高于對(duì)照組(P<0.05)。治療后,兩組P300潛伏期均短于同組治療前,P300波幅均顯著增高(P<0.05);治療后,治療組P300潛伏期、P300波幅改善均優(yōu)于對(duì)照組(P<0.05)。結(jié)論 解郁安神顆粒聯(lián)合氟伏沙明治療抑郁癥具有較好的臨床療效,安全性較佳,能有效促進(jìn)患者抑郁、焦慮癥狀緩解,改善心理健康狀態(tài)、睡眠狀況及日常生活能力,控制病情進(jìn)展,值得臨床推廣應(yīng)用。
[Key word]
[Abstract]
Objective To explore the clinical efficacy of Jieyu Anshen Granules combined with fluvoxamine in treatment of depression. Methods A total of 102 patients with depression admitted to Kailuan Mental Health Center from January 2023 to April 2024 were selected and divided into control group and treatment group according to random number table method, with 51 patients in each group. Patients in the control group were po administered with Fluvoxamine Maleate Tablets before going to bed, 100 mg/time, once daily. Patients in the treatment group were po administered with Jieyu Anshen Granules with boiling water on the basis of the control group, 5 g/time, twice daily. The treatment course of both groups was 6 weeks. The clinical efficacy of two groups was observed. 17 Hamilton Depression Scale (HAMD-17) scores before and after treatment for 2, 4, and 6 weeks, and Self-rating Symptom Scale (SCL-90), Self-rating Sleep Status Scale (SRSS), Ability of Daily Living Scale (ADL) scores and event-related potential P300 parameters were compared between two groups before and after treatment. Results After treatment, the total effective rate of treatment group was 94.12%, which was significantly higher than that of control group (80.39%, P < 0.05). After treatment, HAMD-17 scores in two groups after 2, 4 and 6 weeks of treatment were decreased (P < 0.05). After 2, 4, and 6 weeks of treatment, HAMD-17 scores in treatment groups were lower than those in control group (P < 0.05). After treatment, HAMA, SCL-90 and SRSS scores in two groups were decreased, but ADL scores were significantly increased (P < 0.05). After treatment, HAMA, SCL-90 and SRSS scores in treatment group were lower than those in control group, but ADL scores were higher than those in control group (P < 0.05).
After treatment, the latency of P300 in both groups was shorter than before treatment, but the amplitude of P300 was significantly increased (P < 0.05). After treatment, the improvement of P300 latency and P300 amplitude in treatment group was better than that in control group (P < 0.05). Conclusion Jieyu Anshen Granules combined with fluvoxamine has good clinical efficacy and safety in treatment of depression, and can effectively promote the alleviation of depression and anxiety symptoms in patients, improve mental health status, sleep status and daily living ability, control the progression of the disease, which is worthy of clinical application.
[中圖分類號(hào)]
R971
[基金項(xiàng)目]